ACTIONABILITY KNOWLEDGE REPOSITORY ACTIONABILITY CURATION INTERFACE
Update History
Condition: Wilson Disease
Gene/Gene Panel: ATP7B
Context: Pediatric
Date
Status
Release
Outcomes-Interventions
Notes
2023/06/28
Released
1.0.1
P
Morbidity and mortality from copper deposition (GroupA)
Copper chelation and zinc therapy (GroupA) 11CA
Internal system migration to amend the actionability rationale with respect to the assertion, definitive actionability.
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
ATP7B ⇔ 0010200 WILSON DISEASE; WND
Strong Actionability
Definitive Actionability
2023/06/28
Released (Under revision)
1.0.0
P
Morbidity and mortality from copper deposition (GroupA)
Copper chelation and zinc therapy (GroupA) 11CA
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
ATP7B ⇔ 0010200 WILSON DISEASE; WND
Strong Actionability
Definitive Actionability
2022/07/18
Released
1.0.0
P
Morbidity and mortality from copper deposition (GroupA)
Copper chelation and zinc therapy (GroupA) 11CA
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
ATP7B ⇔ 0010200 WILSON DISEASE; WND
Strong Actionability
Definitive Actionability
2020/02/19
In Preparation
N/A
We have begun assessment of the Pediatric context for this topic
¤ Powered by BCM's Genboree.